Scynexis (SCYX) Liabilities and Shareholders Equity (2013 - 2026)
Scynexis' (SCYX) quarterly Liabilities and Shareholders Equity came in at $75.0 million in Q2 2026, up 23.52% on a YoY basis from $60.7 million in Q2 2025, and down 3.42% quarter-over-quarter from $77.6 million in Q1 2026.
Analysis
Scynexis (SCYX) Liabilities and Shareholders Equity (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $75.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 23.52% year-over-year to $75.0 million; the trailing twelve-month figure through Jun 2026 stood at $262.7 million (down 17.47% YoY), and the FY2025 full-year result was $59.0 million, down 34.88% from the prior year.
- Liabilities and Shareholders Equity declined to $75.0 million in Q2 2026 per SCYX's latest filing, from $77.6 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $154.9 million in Q2 2023 and bottomed at $51.1 million in Q3 2025.
- Historically, Liabilities and Shareholders Equity has averaged $97.6 million across 5 years, with a median of $94.8 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity soared 68.22% in 2024, then tumbled 48.43% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $87.8 million in 2022, then surged by 46.24% to $128.4 million in 2023, then dropped by 29.41% to $90.6 million in 2024, then tumbled by 34.88% to $59.0 million in 2025, then rose by 27.01% to $75.0 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $75.0 million, $77.6 million, and $59.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 10.03 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 10.96 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 5.31 Bn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 74.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 74.97 Mn |
| Mar 31, 2026 | 77.63 Mn |
| Dec 31, 2025 | 59.03 Mn |
| Sep 30, 2025 | 51.07 Mn |
| Jun 30, 2025 | 60.69 Mn |
| Mar 31, 2025 | 67.92 Mn |
| Dec 31, 2024 | 90.64 Mn |
| Sep 30, 2024 | 99.04 Mn |
| Jun 30, 2024 | 107.81 Mn |
| Mar 31, 2024 | 118.25 Mn |
| Dec 31, 2023 | 128.41 Mn |
| Sep 30, 2023 | 148.55 Mn |
| Jun 30, 2023 | 154.86 Mn |
| Mar 31, 2023 | 70.30 Mn |
| Dec 31, 2022 | 87.81 Mn |
| Sep 30, 2022 | 112.29 Mn |
| Jun 30, 2022 | 135.61 Mn |
| Mar 31, 2022 | 111.56 Mn |
| Dec 31, 2021 | 119.84 Mn |
| Sep 30, 2021 | 109.88 Mn |